Patients in the cumulative clinical endpoint cohort were older; more likely to have atrial fibrillation and diabetes mellitus; be in CKD stages 1–3; and have dilated cardiomyopathy, higher LAVI and lower irisin levels than those in the free endpoint cohort. This evidence concerns the gene FNDC5 and dilated cardiomyopathy.